Azitra Inc (AZTR) AI Stock Analysis

• Market Cap: N/A
• Dividend Yield: N/A
• Average Volume (3M): 290.46K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.75
• Revenue Growth: -98.91%
• EPS Growth: 75.80%
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 72
• Industry: Biotechnology
• EPS (TTM): -7.59
• Shares Outstanding: 14,979,354
• 10 Day Avg. Volume: 325,126
• 30 Day Avg. Volume: 290,457
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 659.29
• Price to Cash Flow (P/CF): -0.50
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $3.00
• Price Target Upside: 837.50% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Azitra Inc faces substantial challenges despite notable revenue growth. High operational losses and negative cash flows weigh heavily on its financial health. Technical indicators suggest bearish momentum, and the negative P/E ratio reflects critical valuation concerns. The absence of earnings call data and corporate events leaves these issues unmitigated, resulting in a low overall stock score.

Positive Factors

Clinical Trials

The lead program ATR-12 in Netherton syndrome has dosed the first patient in its P1b study, which is a significant milestone in its clinical development.

Regulatory Progress

The ATR-04 program in EGFRi-associated rash has received IND clearance, marking an important step forward in its development.

Negative Factors

Financial Outlook

Factoring in dilution associated with the two recent financings lowers the 12-month price target to $2.00, from $3.00.

Azitra Inc Business Overview & Revenue Model

Company Description

Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.

How the Company Makes Money

Azitra Inc generates revenue primarily through the development and commercialization of its microbiome-based therapeutics. The company leverages partnerships with pharmaceutical companies and research institutions to advance its product pipeline and bring therapies to market. Revenue streams include licensing agreements, milestone payments, and potential royalties from commercialized products. Additionally, Azitra may obtain funding through research grants and collaborations that support the development of its innovative treatments.

Azitra Inc Financial Statement Overview

Summary

Azitra Inc demonstrates significant revenue growth, which is a positive sign for future potential. However, persistent high losses and negative cash flows indicate underlying operational inefficiencies and financial vulnerabilities. The balance sheet reflects improved equity but high liabilities and substantial cash burn remain critical challenges.

Income Statement

Azitra Inc reported significant revenue growth from $686,000 in 2023 to $7,500,000 in 2024, indicating a positive trajectory in revenue generation. However, the company suffers from extremely high net and operating losses, demonstrated by negative EBIT and EBITDA figures. The net profit margin remains negative due to substantial operational expenses surpassing revenue gains.

Balance Sheet

The balance sheet shows a strong equity position with stockholders' equity of $5,698,298,000 in 2024, reflecting a positive turnaround from negative equity in previous years. The debt-to-equity ratio is low, indicating prudent financial leverage. However, considerable liabilities could pose risks if revenue growth does not continue.

Cash Flow

Negative operating cash flows of -$10,183,740,000 in 2024 highlight cash constraints, limiting operational flexibility. Free cash flow remains deeply negative, though slight improvement is seen from the previous period. The lack of positive cash flows raises concerns about the company's ability to fund operations without external financing.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement		Total Revenue
7.50M	686.00K	284.00K	110.00K
	Gross Profit
7.50M	260.45K	-121.98K	25.23K
	EBIT
-10.99B	-7.62M	-9.45M	-9.22M
	EBITDA
-10.99B	-10.67M	-10.02M	-8.79M
	Net Income Common Stockholders
-8.97M	-11.28M	-10.68M	-8.94M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
4.55B	1.80M	3.49M	8.04M
	Total Assets
7.36B	5.12M	7.17M	10.20M
	Total Debt
555.51M	885.95K	7.73M	992.02K
	Net Debt
-4.00B	-910.04K	4.24M	-7.05M
	Total Liabilities
1.66B	2.20M	43.43M	35.97M
	Stockholders Equity
5.70B	2.91M	-36.26M	-25.77M
Cash Flow		Free Cash Flow
-10.19B	-7.68M	-8.51M	-8.52M
	Operating Cash Flow
-10.18B	-7.36M	-8.35M	-8.07M
	Investing Cash Flow
-379.25M	-318.26K	-336.76K	-652.27K
	Financing Cash Flow
13.32M	5.98M	4.13M	992.86K

Azitra Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.32
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AZTR, the sentiment is Negative. The current price of 0.32 is above the 20-day moving average (MA) of 0.30, below the 50-day MA of 0.33, and below the 200-day MA of 0.62, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 42.34 is Neutral, neither overbought nor oversold. The STOCH value of 54.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AZTR.

Azitra Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KRYS	77 Outperform	$4.87B	56.42	10.34%	―	473.02%	1620.44%
DERM	57 Neutral	$143.48M	―	-72.60%	―	-29.11%	-219.44%
Sector *	50 Neutral	$5.51B	2.95	-43.70%	2.78%	16.94%	3.59%
FBIO	42 Neutral	$44.30M	―	-203.16%	―	-31.76%	86.19%
AZTR	39 Underperform		―	-208.27%	―	-98.91%	75.80%
FBRX	38 Underperform	$47.78M	―	-80.82%	―	―	43.64%